Benefit-risk assessment of interferon-b therapy for relapsing multiple sclerosis

ISSN： 1474-0338

Source： Expert Opinion on Drug Safety, Vol.3, Iss.4, 2004-07, pp. : 289-303

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Risk-Benefit Assessment of Glatiramer Acetate in Multiple Sclerosis

By Ziemssen T.

Drug Safety, Vol. 24, Iss. 13, 2001-01 ,pp. : 979-990

Adis International

Access to resources Recommend Favorite

Interferon-β-1b of benefit in early multiple sclerosis

Inpharma, Vol. 1, Iss. 1512, 2005-01 ,pp. : 13-14

Adis International

Access to resources Recommend Favorite

The Mechanism of Action of Interferon-β in Relapsing Multiple Sclerosis

By Kieseier Bernd C.

CNS Drugs, Vol. 25, Iss. 6, 2011-06 ,pp. : 491-502

Adis International

Access to resources Recommend Favorite

Interferon- -1b: A Review of its Use in Relapsing-Remitting and Secondary Progressive Multiple Sclerosis

By McCormack P.L. Scott L.J.

CNS Drugs, Vol. 18, Iss. 8, 2004-01 ,pp. : 521-546

Adis International

Access to resources Recommend Favorite

A Population Approach to Characterize Interferon Beta‐1b Effect on Contrast Enhancing Lesions in Patients With Relapsing Remitting Multiple Sclerosis

Cpt: Pharmacometrics & Systems Pharmacology, Vol. 4, Iss. 5, 2015-05 ,pp. : 295-304

John Wiley & Sons Inc

Access to resources Recommend Favorite